NCT00028067终止3 期
A Phase III Study Comparing the Antiviral Efficacy and Safety of Atazanavir With Nelfinavir: Each in Combination With Dual Nucleoside Therapy in HIV-Infected Subjects Who Have Failed a Regimen Not Containing a Protease Inhibitor
Bristol-Myers Squibb62 个研究点 分布在 4 个国家目标入组 500 人开始时间: 2001年8月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 入组人数
- 500
- 试验地点
- 62
研究概览
简要总结
The purpose of this study is to compare the atazanavir and nelfinavir (NFV) treatments in their ability to reduce viral load.
详细描述
In this double-blind, double-placebo, randomized, 2-arm study, atazanavir and NFV each are given in combination with 2 open-label nucleoside reverse transcriptase inhibitors (NRTIs) over 48 weeks. Patients assigned to atazanavir will receive placebo capsules which are identical in size and appearance to NFV. Patients assigned to NFV will receive placebo capsules which are identical in size and appearance to atazanavir. HIV levels are monitored.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients may be eligible for this study if they:
- •Have a viral load of 1000 or more copies/ml within 3 weeks before randomization. Have a CD4 cell count of 50 or more cells/mm3 within 3 weeks prior to randomization.
- •Are at least 16 years old (or the minimum age by local requirements).
- •Have had more than 16 weeks of therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) and/or nucleoside reverse transcriptase inhibitor (NRTI).
- •Use effective barrier method of contraception.
- •Give written informed consent.
- •Are available for follow-up for at least 52 weeks.
排除标准
- •Patients may not be eligible for this study if they:
- •Have used a protease inhibitor (PI) treatment for more than 7 days or within 30 days prior to screening.
- •Have a newly-diagnosed HIV-related infection or any medical condition requiring relatively short but intense therapy at the time of enrollment.
- •Have hepatitis in the 30 days before the study. Patients with long-term hepatitis are eligible if their liver function meets certain requirements.
- •Are unable to demonstrate responsiveness to a provided NRTI.
- •Have had previous or expect a need for therapy with agents that may cause damage to nerve tissue, the pancreas, the liver, bone marrow, or cells within 3 months of study start.
- •Use too much alcohol or drugs to be able to follow the study therapy; or if they use enough to increase the risk of developing pancreatitis or chemical hepatitis.
- •Have severe diarrhea within 30 days prior to study entry.
- •Are pregnant or breast-feeding.
- •Have a history of hemophilia.
- •Have history or signs of bilateral peripheral neuropathy.
- •Have cardiomyopathy.
- •Have certain heart problems.
- •Cannot tolerate oral medication.
- •Have any other problems that would interfere with the study.
研究者
研究点 (62)
Loading locations...
相似试验
已完成
不适用
A Phase III Study Comparing the Antiviral Efficacy and Safety of BMS-232632 with Efavirenz; Each in Combination with Fixed Dose Zidovudine-Lamivudine-B22 Human immunodeficiency virus [HIV] disease resulting in other specified diseasesHuman immunodeficiency virus [HIV] disease resulting in other specified diseasesB22PER-076-00BRISTOL MYERS SQUIBB PERU S.A.,
已完成
4 期
Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)HIV InfectionsNCT00552240Boehringer Ingelheim154
已完成
4 期
Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation CohortHIV InfectionsNCT00618176Peking Union Medical College198
终止
3 期
A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B InfectionChronic Hepatitis BNCT00605384Bristol-Myers Squibb4
已完成
3 期
BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose TruvadaHIV InfectionsNCT00272779Bristol-Myers Squibb1,057